Adaptimmune draws investor buzz, fourth cancer trial launched
This article was originally published in Scrip
Executive Summary
UK biotechnology firm Adaptimmue's steadily growing number of clinical trials involving its early-stage, cancer-targeting, gene-engineered T-cell receptor technology is acting as honey to potential licensees, the company says.